April 2 (Reuters) - Hikma Pharmaceuticals Plc saidon Wednesday that the U.S. Food and Drug Administration hadlifted the warning on its Eatontown facility in New Jersey whereit makes oral products for the U.S. market.
The Jordanian company, which makes and markets branded andnon-branded generics and injectibles, said it was graduallyreintroducing products to the U.S. market from the facility.
The company had suspended manufacturing at the plant in 2012after receiving an FDA warning letter. Hikma said correctiveactions have been taken in response to the letter.
Hikma's Eatontown facility underwent extensive remediationwork in 2013 and was reinspected by the U.S. FDA in February2014. (Reporting by Esha Vaish in Bangalore; Editing by Joyjeet Das)
Hikma Pharmaceuticals (HIK)
